Ep. Chen et al., PULMONARY VASCULAR IMPEDANCE AND RECIPIENT CHRONIC PULMONARY-HYPERTENSION FOLLOWING CARDIAC TRANSPLANTATION, Chest, 112(6), 1997, pp. 1622-1629
Study objectives: Recipient chronic pulmonary hypertension (CPH), seco
ndary to long-standing congestive heart failure, represents a signific
ant risk factor for right ventricular (RV) dysfunction following ortho
topic cardiac transplantation (TX). This study was designed to charact
erize the changes occurring in pulmonary hemodynamics, pre-TX and post
-TX, using Fourier analysis, a canine model of bicaval TX, and monocro
taline pyrrole (MCTP)-induced recipient CPH. Design: Prospective, cont
rolled study. Setting: Experimental laboratory. Participants: Twenty a
dult male mongrel dogs (23 to 26 kg). Interventions: Recipients underw
ent pulmonary artery injection of 3 mg/kg MCTP 4 months pre-TX. On the
day of TX, donor hearts were instrumented with an ultrasonic flow pro
be and micromanometers. Harmonic derivation of functional data was ach
ieved with Fourier analysis. Measurements and results: At the time of
TX, significant increases were observed in the mean pulmonary artery p
ressure and pulmonary vascular resistance of recipient animals in comp
arison to donors, which were further significantly increased following
the termination of cardiopulmonary bypass. Significant increases were
also observed in the input resistance, characteristic impedance, and
RV hydraulic power post-TX compared to pre-TX, and occurred in associa
tion with a significant decrease in the transpulmonary efficiency. Con
clusions: Zn the setting of MCTP-induced recipient CPH donor hearts we
re exposed to significant alterations in cardiopulmonary hemodynamics
following bicaval TX. Pulmonary blood flow is maintained by a signific
antly higher energy expenditure by the RV, but at a lower level of eff
iciency. This experimental model may provide a useful means by which t
o evaluate therapeutic options to better manage cardiopulmonary hemody
namics in order to prevent RV failure following TX in the setting of r
ecipient CPH.